Sintilimab plus Bevacizumab biosimilar IBI305 and chemotherapy as a first-line treatment in advanced gastric or gastroesophageal junction adenocarcinoma (SBAGA): a single-arm, phase Ib/II study

Mo Cheng, Pengfei Zhang, Qiancheng Hu, Jitao Zhou, Ruihong Dai, Wenke Li, Jing Wei, Menghui Xu, Yanna Lei, Xiaoying Li, Xiufeng Zheng, Qian Huang, Zhiping Li, Bo Zhang, Wen Zhuang, Zhixin Chen, Xiaolong Chen, Chaoyong Shen, Weihan Zhang, Kai Liu, Linyong Zhao, Xiaonan Yin, Boqiang Peng, Zhaolun Cai, Yuan Yin, Ji Chen, Chunjuan Liu, Deying Kang, Mojin Wang, Hongfeng Gou, Kun Yang, Jiankun Hu, Feng Bi, Ming Liu

Open source

DOI: 10.1038/s41467-026-76502-7
Published: 2026-08-15
Container: Nature Communications
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41467-026-76502-7,
  title = {Sintilimab plus Bevacizumab biosimilar IBI305 and chemotherapy as a first-line treatment in advanced gastric or gastroesophageal junction adenocarcinoma (SBAGA): a single-arm, phase Ib/II study},
  author = {Mo Cheng and Pengfei Zhang and Qiancheng Hu and Jitao Zhou and Ruihong Dai and Wenke Li and Jing Wei and Menghui Xu and Yanna Lei and Xiaoying Li and Xiufeng Zheng and Qian Huang and Zhiping Li and Bo Zhang and Wen Zhuang and Zhixin Chen and Xiaolong Chen and Chaoyong Shen and Weihan Zhang and Kai Liu and Linyong Zhao and Xiaonan Yin and Boqiang Peng and Zhaolun Cai and Yuan Yin and Ji Chen and Chunjuan Liu and Deying Kang and Mojin Wang and Hongfeng Gou and Kun Yang and Jiankun Hu and Feng Bi and Ming Liu},
  year = {2026},
  journal = {Nature Communications},
  doi = {10.1038/s41467-026-76502-7},
  url = {https://doi.org/10.1038/s41467-026-76502-7}
}

RIS

TY  - JOUR
TI  - Sintilimab plus Bevacizumab biosimilar IBI305 and chemotherapy as a first-line treatment in advanced gastric or gastroesophageal junction adenocarcinoma (SBAGA): a single-arm, phase Ib/II study
AU  - Mo Cheng
AU  - Pengfei Zhang
AU  - Qiancheng Hu
AU  - Jitao Zhou
AU  - Ruihong Dai
AU  - Wenke Li
AU  - Jing Wei
AU  - Menghui Xu
AU  - Yanna Lei
AU  - Xiaoying Li
AU  - Xiufeng Zheng
AU  - Qian Huang
AU  - Zhiping Li
AU  - Bo Zhang
AU  - Wen Zhuang
AU  - Zhixin Chen
AU  - Xiaolong Chen
AU  - Chaoyong Shen
AU  - Weihan Zhang
AU  - Kai Liu
AU  - Linyong Zhao
AU  - Xiaonan Yin
AU  - Boqiang Peng
AU  - Zhaolun Cai
AU  - Yuan Yin
AU  - Ji Chen
AU  - Chunjuan Liu
AU  - Deying Kang
AU  - Mojin Wang
AU  - Hongfeng Gou
AU  - Kun Yang
AU  - Jiankun Hu
AU  - Feng Bi
AU  - Ming Liu
PY  - 2026
JO  - Nature Communications
DO  - 10.1038/s41467-026-76502-7
UR  - https://doi.org/10.1038/s41467-026-76502-7
ER  -

APA

Cheng, M., Zhang, P., Hu, Q., Zhou, J., Dai, R., Li, W., Wei, J., Xu, M., Lei, Y., Li, X., Zheng, X., Huang, Q., Li, Z., Zhang, B., Zhuang, W., Chen, Z., Chen, X., Shen, C., Zhang, W., Liu, K., Zhao, L., Yin, X., Peng, B., Cai, Z., Yin, Y., Chen, J., Liu, C., Kang, D., Wang, M., Gou, H., Yang, K., Hu, J., Bi, F., & Liu, M. (2026). Sintilimab plus Bevacizumab biosimilar IBI305 and chemotherapy as a first-line treatment in advanced gastric or gastroesophageal junction adenocarcinoma (SBAGA): a single-arm, phase Ib/II study. Nature Communications. https://doi.org/10.1038/s41467-026-76502-7

Source records

crossref · retrieved 2026-09-26T15:00:41.867Z